NEW YORK, May 4, 2021 /PRNewswire/ -- U.S. patent number
10,980,865 [Application Number 14/909,954] was granted to Aquavit
Pharmaceuticals, Inc. for direct application system and method
for the delivery of bioactive compositions and formulations.
The invention utilizes a "repeated motion" delivery technology
(AQT Technology), creating a new route of administration (RoA) and
mode of administration (MoA) for the pharmaceutical and
biotechnology industry for the first time in decades.
The embodiments also relate to improved skin quality, health and
appearance using a new delivery method and certain bioactive
compositions and formulations such as botulinum toxin, hyaluronic
acid, poly-L-lactic acid (PLLA), collagen, vitamins, minerals, stem
cell, platelet-rich plasma (PRP), retinols, antioxidants, growth
factors, bimatoprost and/or minoxidil to act on the skin, into the
skin and/or subcutaneous muscles in order to boost cell
rejuvenation and creation, alleviate fine lines and wrinkles,
reduce the appearance of scars and blemishes, and improve skin
quality, clarity, elasticity, firmness, tone, vitality, and overall
skin health.
"This patent combined with our recent acquisition of a License
for a new botulinum toxin asset will ignite many advancements in
the industry and provide limitless opportunities for New Drug
Applications (NDA) or Biologics License Applications (BLA)." says
Sobin Chang, MPH., CEO of Aquavit.
"It has taken many years to get this patent granted. We are
thrilled and looking forward to accelerating our developments and
collaborations."
The invention adds a new RoA/MoA for the FDA for the first time
in decades. RoAs are currently limited to simple injection (IV, IM,
subQ), topical, oral, nasal spray, inhaler, and patches. Using this
novel technology, "repeated motion of embroidery-like
microinjections", results in virtually no pain, bruising or
bleeding while administering efficient treatments to broader areas
of the skin. Compared to patches (including those utilizing micro
needles), AQT technology allows significantly faster onset of
delivery. Another contrast to general topical route of
administration, efficacy and bioavailability is enhanced
significantly. In medical aesthetics, the technology can help
achieve optimal quality skin health, instead of temporary
superficial results.
"We live in a great age with many technological advances. As a
plastic surgeon and medical innovator, I am proud of the advances
we have made with Aquavit." says Dr. David
Shafer, a renowned plastic surgeon and Aquavit's Chief
Medical Technology Officer. "Under the leadership of Sobin Chang, Aquavit continues to push the
envelope in the aesthetic space - bridging technology and medical
treatments."
The technology can also be translated well into delivering drugs
and biologics for skin cancer, immunology and dermatological
conditions. In the field of oncology, diseases such as actinic
keratosis and basal cell carcinoma, the unmet needs are the issue
of tolerability and patient compliance while delivering
chemotherapy drugs. This technology will directly address these
issues by minimizing systemic toxicity while delivering potent
therapeutic agents directly onto the affected skin site. Vaccines
can be delivered epidermally through this technology. The
intradermal delivery has enormous advantages over existing
commercial vaccines, which are delivered to intramuscular or
subcutaneous tissues by needle and syringe. The technology provides
targeted delivery to the epidermis which is rich with APCs, the
Langerhans cells (LCs), which aid in the effective functioning of
vaccines. It will result in increased immunogenicity. In addition,
the patent covers broadly the method for treating or ameliorating
other diseases and conditions, including depression, dementia,
fibromyalgia, gastrointestinal disorder, headaches, chronic fatigue
syndrome, high stress levels, hyperthyroidism, low energy, impaired
memory, hair loss, wound healing, scarring, and aging.
"This unique development allows for the pursuit of personalized
medicine, including the potential for self-administered treatment
delivery." says Sai Sankar, Aquavit's Chief Biomedical Engineer.
"Secured by a high-tech proprietary system, there is unlimited
potential in using AQT technology, including 3-D printing of
biodegradable microchips that can be delivered via injection, AQT
or any other possible route. This patent allows for the pursuit of
personalized medicine, or treatment delivery that can expand to
remote controlled environments, immediate compounding and ultimate
personalization with a state of the art longitudinal data
predictive analytics creating certain formulations that are unique,
combinatory and synergistic."
About Aquavit Pharmaceuticals, Inc.
Aquavit Pharmaceuticals, Inc. is a high-tech pharmaceutical
company that provides a comprehensive range of innovative
pharmaceutical, biotech and medical device technologies. Aquavit
Pharmaceuticals, Inc. focuses on personalized medicine to improve
patients' health, maximize the efficiency of our medical community,
and support the pharmacoeconomics of payers.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/patent-granted-to-aquavit-for-novel-roa-and-moa-for-bioactive-compositions-301283497.html
SOURCE Aquavit Pharmaceuticals, Inc.